Tandem Diabetes Care, Inc. reported a significant increase in revenue for the fiscal year ended December 31, 2025, achieving total sales of $1.015 billion, up from $940.2 million in 2024. This growth was driven by a rise in both domestic and international sales, with U.S. sales reaching $706.9 million, a 5.1% increase from the previous year, and international sales rising to $307.8 million, a 15% increase. Despite this revenue growth, the company reported a net loss of $204.7 million, compared to a net loss of $96 million in 2024, primarily due to increased operating expenses and costs associated with acquired in-process research and development.
The company's operating expenses rose to $733.3 million in 2025, up from $588.7 million in 2024. This increase was largely attributed to higher selling, general, and administrative expenses, which included one-time charges for facility impairments and restructuring costs. Research and development expenses decreased slightly to $193.1 million, reflecting a focus on efficiency. The company also incurred $75.2 million in acquired in-process research and development expenses related to its acquisition of AMF Medical, which is developing the Sigi Patch Pump.
Tandem's customer base expanded to nearly 500,000 individuals living with diabetes across more than 25 countries. The company shipped over 126,000 insulin pumps in 2025, a slight increase from the previous year. The introduction of the Tandem Mobi insulin pump, which features advanced technology and was made available to Android users in December 2025, is expected to enhance customer engagement and product adoption. The company is also transitioning to a multi-channel managed care strategy in the U.S., allowing for reimbursement through pharmacy benefits, which may further increase accessibility and sales.
Looking ahead, Tandem Diabetes Care anticipates continued growth driven by its innovative product offerings and strategic initiatives. However, the company faces challenges, including the need to secure adequate reimbursement coverage and navigate a competitive landscape with established players like Medtronic and Insulet. The management's focus on expanding its product portfolio and enhancing customer retention through improved service and support will be critical to achieving its long-term financial goals. The company remains committed to investing in research and development to drive future growth and improve diabetes management solutions.
About TANDEM DIABETES CARE INC
Tandem Diabetes Care designs and manufactures advanced insulin delivery systems, including insulin pumps with Control-IQ technology, for people with insulin-dependent diabetes. Its products serve primarily type 1 and type 2 diabetes patients worldwide, offering automated insulin management, connectivity, and data insights. The company’s business model focuses on innovation, regulatory compliance, and global distribution through direct and partner channels.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.